Effectiveness of Oculomotor Training in Parkinson's Disease

September 19, 2022 updated by: Allen MY Cheong, The Hong Kong Polytechnic University

Oculomotor Deficits in Parkinson's Disease: Enhancing Eye Movement Performance and Dynamic Visual Acuity With Oculomotor Training Using a Pilot Randomized Clinical Trial Design

Parkinson's disease (PD) is a common neurodegenerative disorder which is characterized by both motor and non-motor symptoms and usually affects people aged 50 years or above. Many studies showed eye movement deficits and visual changes in patients with PD.

Previous studies have also indicated that clinical eye movement training could enhance the functional performance of patients with various eye movement problems resulting from ocular and neurodegenerative diseases.

In this study, we will investigate the effectiveness of eye movement training on dynamic vision and functional performance in PD patients with oculomotor deficits.

Study Overview

Status

Enrolling by invitation

Study Type

Interventional

Enrollment (Anticipated)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Hong Kong, Hong Kong
        • Allen MY Cheong

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Parkinson's Disease diagnosed by a neurologist or geriatrician with the range of Stage

    1 to 4 (Hoehn and Yahr Classification)

  • Able to speak and comprehend Cantonese dialect
  • Able to travel independently

Exclusion Criteria:

  • Any congenital eye problem (e.g. congenital strabismus or amblyopia in either eye) or any manifest eye diseases (e.g. macular degeneration, glaucoma, etc)
  • Severe medical problems (e.g. stroke)
  • Cognitive impairment (e.g. dementia)
  • Presence of any psychiatric or neurological diseases (apart from Parkinson's disease) or receiving of any psychoactive pharmacological treatment
  • Receiving any medication that is known to affect eye movement and cognitive function
  • Previous formal vision rehabilitation or oculomotor intervention

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Control Group
Receive 10 sessions of 45-minute (3 sessions per week) in-office leisure activities e.g. simple non-action computer games or board games (e.g. card and chess games) and 10-20 minutes of video watching at home
Leisure activities
Active Comparator: Intervention Group
Receive 10 sessions of 45-minute office training (3 sessions per week) and 10-20 minute home training (3 sessions per week) of eye movement training
Eye movement training

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Smooth Vergence eye movements
Time Frame: Change from baseline at week 4 and change from baseline at week 12
Smooth vergence eye movement is measured using a head-mounted eye tracking while fixating at an approaching target moving at different speeds
Change from baseline at week 4 and change from baseline at week 12

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oculomotor characteristics
Time Frame: Change from baseline at week 4 and change from baseline at week 12

With the use of eye tracking device, eye movement behavior of participants can be measured and analysed while performing the following tasks.

  1. Fixation task - Fixate at stationary target presented on a monitor
  2. Saccade task - Follow and fixate at a random jumping target presented on a monitor
  3. Pursuit task - Follow accurately and steadily on a smooth moving target presented on a monitor
  4. Jump Vergence task - Follow and fixate a jumping target presented in the anterior-posterior plane (jumping from 'far to near' or 'near to far')
Change from baseline at week 4 and change from baseline at week 12
Sentence reading performance
Time Frame: Change from baseline at week 4 and change from baseline at week 12
To evaluate the effectiveness of the interventions on sentence reading using MNREAD charts in Chinese. These charts developed in our laboratory are used to measure the effectiveness of sentence reading in terms of reading speed and critical print size.
Change from baseline at week 4 and change from baseline at week 12
Passage reading performance
Time Frame: Change from baseline at week 4 and change from baseline at week 12
To evaluate the effectiveness of the interventions on passage reading using International Reading speed Test (IReST). IReST is used to evaluate the effectiveness of passage reading performance by measuring the reading speed.
Change from baseline at week 4 and change from baseline at week 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Allen Ming Yan Cheong, PhD, The Hong Kong Polytechnic University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 3, 2020

Primary Completion (Actual)

August 31, 2022

Study Completion (Anticipated)

December 1, 2022

Study Registration Dates

First Submitted

September 7, 2020

First Submitted That Met QC Criteria

September 22, 2020

First Posted (Actual)

September 23, 2020

Study Record Updates

Last Update Posted (Actual)

September 21, 2022

Last Update Submitted That Met QC Criteria

September 19, 2022

Last Verified

September 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson Disease

Clinical Trials on Control Group

3
Subscribe